The goal of this clinical research study is to learn if pazopanib can help to control Von
Hippel-Lindau Syndrome VHL. The safety of this drug will also be studied.
This is an investigational study. Pazopanib is FDA approved and commercially available for
kidney cancer. Its use to treat VHL is investigational.
Pazopanib is designed to block the growth of blood vessels that supply nutrients needed for
tumor growth. This may prevent or slow the growth of cancer cells.
Pazopanib will be provided at no cost to you during this study.
Up to 40 patients will take part in this study. All will be enrolled at MD Anderson.